Biotech defies calls to sack McCullagh
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.BRITISH BIOTECH confirmed yesterday that it had no plans to sack Keith McCullagh, its chief executive, despite growing pressure to do so from some institutional shareholders.
The spokeswoman for the group said that it plans to rush out a circular to shareholders "as soon as possible" to counter allegations by Dr Andrew Millar, its former clinical research director who has attacked the way British Biotech has handled its drug development programme.
However British Biotech is not planning to unveil any management changes in the circular. Instead it will cover its approach to the research and development programme and include a year end cash balance.
However the group still appears to be on a collision course with some institutional shareholders who are unhappy with Mr McCullagh's present role.
British Biotech acknowledged yesterday that some of its directors could face legal action in the US from the Securities and Exchange Commission which has launched an investigation into allegations that press releases from the group painted an over-optimistic picture of the prospects for marimastat, a cancer treatment.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments